{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:07:25Z","timestamp":1790856445396,"version":"4.1.0"},"reference-count":31,"publisher":"BioExcel","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Cutaneous pseudolymphomas (CPLs) comprise a heterogeneous group of benign lymphoid proliferations that simulate cutaneous lymphomas both clinically and histologically. Numerous causes have been identified, including infections, arthropod bites, tattoos and drugs. With the expanding use of biologic therapies for chronic inflammatory dermatoses, a growing number of drug-related CPLs have been reported. Although tumour necrosis factor inhibitors are most frequently implicated, emerging evidence suggests that other biologic therapy classes may also trigger lymphoid hyperplasia through immune dysregulation. We provide a concise narrative review of biologics-induced CPLs and illustrate the topic with the first reported case of brodalumab-induced pseudolymphoma in a patient with psoriasis. Understanding this rare adverse event is crucial for early recognition, correct histopathological interpretation and appropriate management.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summary-biologics-induced-cutaneous-pseudolymphomas-a-narrative-review-with-an-illustrative-case-of-brodalumab-induced-pseudolymphoma<\/jats:p>","DOI":"10.7573\/dic.2025-10-5","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:05:41Z","timestamp":1771841141000},"page":"1","source":"Crossref","is-referenced-by-count":1,"title":["Biologics-induced cutaneous pseudolymphomas: a narrative review with an illustrative case of brodalumab-induced pseudolymphoma"],"prefix":"10.7573","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0669-5366","authenticated-orcid":false,"given":"Gustavo","family":"Almeida-Silva","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/031xaae12","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade Santa Maria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4497-9763","authenticated-orcid":false,"given":"In\u00eas","family":"Tribolet de Abreu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/031xaae12","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade Santa Maria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9950-1521","authenticated-orcid":false,"given":"Filipe","family":"Monteiro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/031xaae12","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade Santa Maria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"de Vasconcelos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/031xaae12","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade Santa Maria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Filipe","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/031xaae12","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade Santa Maria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Antunes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/031xaae12","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade Santa Maria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tGuo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437. https:\/\/doi.org\/10.1038\/s41392-023-01655-6","DOI":"10.1038\/s41392-023-01655-6"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tPapp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u2013286. https:\/\/ doi.org\/10.1111\/bjd.14493","DOI":"10.1111\/bjd.14493"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tLebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u20131328. https:\/\/doi.org\/10.1056\/NEJMoa1503824","DOI":"10.1056\/NEJMoa1503824"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tCerroni L. Skin lymphoma: the illustrated guide. 5th ed. John Wiley & Sons; 2020.","DOI":"10.1002\/9781119485933"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tEtesami I, Kalantari Y, Tavakolpour S, Mahmoudi H, Daneshpazhooh M. Drug-induced cutaneous pseudolymphoma: a systematic review of the literature. Australas J Dermatol. 2023;64(1):41\u201349. https:\/\/doi.org\/ 10.1111\/ajd.13951","DOI":"10.1111\/ajd.13951"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tSchmutz JL, Trechot P. Cutaneous pseudolymphoma with two types of anti-TNF\u03b1: a class effect? Ann Dermatol Venereol. 2012;139(10):695\u2013696. https:\/\/doi.org\/10.1016\/j.annder.2012.05.019","DOI":"10.1016\/j.annder.2012.05.019"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tNikolaou V, Gerochristou M, Marinos L, et al. Lymphoproliferative skin reactions induced by anti-TNF\u03b1: an open question. J Dermatolog Treat. 2020;31(1):99\u2013102. https:\/\/doi.org\/10.1080\/09546634.2019.1579889","DOI":"10.1080\/09546634.2019.1579889"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tRobert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med. 1999;341(24): 1817\u20131828. https:\/\/doi.org\/10.1056\/NEJM199912093412407","DOI":"10.1056\/NEJM199912093412407"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tImafuku S, Ito K, Nakayama J. Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis. Br J Dermatol. 2012;166(3):675\u2013678. https:\/\/doi.org\/10.1111\/j.1365- 2133.2011.10607.x","DOI":"10.1111\/j.1365-2133.2011.10607.x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tImafuku S, Tatsukawa R, Ito K, Nakayama J. Cutaneous pseudolymphoma caused by tumor necrosis factor-\u03b1 inhibitors was not induced by ustekinumab. J Dermatol. 2012;39(12):1070\u20131071. https:\/\/doi.org\/10.1111\/j.1346- 8138.2012.01602.x","DOI":"10.1111\/j.1346-8138.2012.01602.x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tSafa G, Luce K, Darrieux L, Tisseau L, Ortonne N. Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy. J Am Acad Dermatol. 2014;71(4):e149\u2013e150. https:\/\/doi.org\/10.1016\/j.jaad.2014.05.042","DOI":"10.1016\/j.jaad.2014.05.042"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tCarvalhana S, Gon\u00e7alves A, Velosa J. Cutaneous pseudolymphoma in a patient with Crohn\u2019s disease under infliximab: first report. J Clin Gastroenterol. 2016;50(5):436\u2013437. https:\/\/doi.org\/10.1097\/MCG.0000000000000513","DOI":"10.1097\/MCG.0000000000000513"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tCranwell WC, Doolan BJ, Radulski B, Nicolopoulos J, Dolianitis C. Pseudolymphoma induced by secukinumab for treatment of chronic plaque psoriasis. Australas J Dermatol. 2019;60(3):e246\u2013e248. https:\/\/doi.org\/10.1111\/ajd.13009","DOI":"10.1111\/ajd.13009"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tAo J, Curragh DS, Otto S, Selva D. Ocular adnexal B-cell hyperplasia associated with adalimumab. Clin Experiment Ophthalmol. 2019;47(8):1096\u20131097. https:\/\/doi.org\/10.1111\/ceo.13582","DOI":"10.1111\/ceo.13582"},{"key":"ref14","unstructured":"15.\tGuis S, Schiano De Colella JM, Bonnet N, et al. Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept. Eur J Dermatol. 2008;18(4):474\u2013476. https:\/\/doi.org\/10.1684\/ejd.2008.0457"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tMitteldorf C, Kempf W. Cutaneous pseudolymphoma \u2013 a review on the spectrum and a proposal for a new classification. J Cutan Pathol. 2020;47(1):76\u201397. https:\/\/doi.org\/10.1111\/cup.13532","DOI":"10.1111\/cup.13532"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tMagro CM, Daniels BH, Crowson AN. Drug induced pseudolymphoma. Semin Diagn Pathol. 2018;35(4):247\u2013259. https:\/\/doi.org\/10.1053\/j.semdp.2017.11.003","DOI":"10.1053\/j.semdp.2017.11.003"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tRijlaarsdam JU, Meijer CJ, Willemze R. Differentiation between lymphadenosis benigna cutis and primary cutaneous follicular center cell lymphomas. A comparative clinicopathologic study of 57 patients. Cancer. 1990;65(10):2301\u20132306. https:\/\/doi.org\/10.1002\/1097-0142(19900515)65:10%3C2301::aid-cncr2820651023%3E3.0.co;2-m","DOI":"10.1002\/1097-0142(19900515)65:10<2301::AID-CNCR2820651023>3.0.CO;2-M"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tCerroni L, Kerl H. Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Semin Cutan Med Surg. 1999;18(1):64\u201370. https:\/\/doi.org\/10.1016\/s1085-5629(99)80010-8","DOI":"10.1016\/S1085-5629(99)80010-8"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tCerroni L, Minkus G, P\u00fctz B, H\u00f6fler H, Kerl H. Laser beam microdissection in the diagnosis of cutaneous B-cell lymphoma. Br J Dermatol. 1997;136(5):743\u2013746.","DOI":"10.1111\/j.1365-2133.1997.tb03663.x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tAyoubi N, Haque A, Vera N, Ma S, Messina J, Khushalani N, Seminario-Vidal L. Ipilimumab\/nivolumab-induced pseudolymphoma in a patient with malignant melanoma. J Cutan Pathol. 2020;47(4):390\u2013393. https:\/\/doi.org\/ 10.1111\/cup.13604","DOI":"10.1111\/cup.13604"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tSangueza OP, Yadav S, White Jr CR, et al. Evolution of B-cell lymphoma from pseudolymphoma. A multidisciplinary approach using histology, immunohistochemistry, and Southern blot analysis. Am J Dermatopathol. 1992;14: 408\u2013413. https:\/\/doi.org\/10.1097\/00000372-199210000-00006","DOI":"10.1097\/00000372-199210000-00006"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tKulow BF, Cualing H, Steele P, et al. Progression of cutaneous B-cell pseudolymphoma to cutaneous B-cell lymphoma. J Cutan Med Surg. 2002;6:519\u2013528. https:\/\/doi.org\/10.1007\/s10227-001-0133-7","DOI":"10.1177\/120347540200600601"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tChen XY, Liu WZ, Shi Y, et al. Helicobacter pylori associated gastric diseases and lymphoid tissue hyperplasia in gastric antral mucosa. J Clin Pathol. 2002;55:133\u2013137. https:\/\/doi.org\/10.1136\/jcp.55.2.133","DOI":"10.1136\/jcp.55.2.133"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tSaxena A, Moshynska O, Kanthan R, Bhutani M, Maksymiuk AW, Lukie BE. Distinct B-cell clonal bands in Helicobacter pylori gastritis with lymphoid hyperplasia. J Pathol. 2000;190(1):47\u201354. https:\/\/doi.org\/10.1002\/ (SICI)1096-9896(200001)190:1%3C47::AID-PATH506%3E3.0.CO;2-O","DOI":"10.1002\/(SICI)1096-9896(200001)190:1<47::AID-PATH506>3.0.CO;2-O"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tNihal M, Mikkola D, Horvath N, et al. Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol. 2003;34:617\u2013622. https:\/\/doi.org\/10.1016\/s0046-8177(03)00075-3","DOI":"10.1016\/S0046-8177(03)00075-3"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tCerroni L, Zochling N, Putz B, et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24:457\u2013461. https:\/\/doi.org\/10.1111\/j.1600-0560.1997.tb01318.x","DOI":"10.1111\/j.1600-0560.1997.tb01318.x"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tHammer E, Sangueza O, Suwanjindar P, et al. Immunophenotypic and genotypic analysis in cutaneous lymphoid hyperplasias. J Am Acad Dermatol. 1993;28:426\u2013433. https:\/\/doi.org\/10.1016\/0190-9622(93)70063-y","DOI":"10.1016\/0190-9622(93)70063-Y"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tLeBoit PE. Cutaneous lymphocytic infiltrates: let\u2019s get real. Am J Dermatopathol. 2005;27(2):182\u2013184. https:\/\/doi.org\/ 10.1097\/01.dad.0000164547.13166.36","DOI":"10.1097\/01.dad.0000164547.13166.36"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tBryant RJ, Banks PM, O\u2019Malley DP. Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology. 2006;48(5):505\u2013515. https:\/\/doi.org\/10.1111\/j.1365-2559.2006.02378.x","DOI":"10.1111\/j.1365-2559.2006.02378.x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tBosisio FM, Cerroni L. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas. Am J Dermatopathol. 2015;37:115\u2013121. https:\/\/doi.org\/ 10.1097\/DAD.0000000000000258","DOI":"10.1097\/DAD.0000000000000258"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/02\/dic.2025-10-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:25:18Z","timestamp":1790853918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/biologics-induced-cutaneous-pseudolymphomas-a-narrative-review-with-an-illustrative-case-of-brodalumab-induced-pseudolymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-10-5","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"dic.2025-10-5"}}